TargetBeta
SMURF1
SMAD specific E3 ubiquitin protein ligase 1 · also KIAA1625 · Nedd4 family E3 ubiquitin protein ligases
1 program in company-led studies act on SMURF1, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Idiopathic Pulmonary Fibrosis, 1 program
- Pulmonary Arterial Hypertension, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.